ANP32A: Acidic Nuclear Phosphoprotein 32 Family Member A
A multifunctional regulator of gene expression, apoptosis, and tumor suppression, implicated in cancer and neurological disorders.
Gene Information Card
| Symbol | ANP32A |
|---|---|
| Full Name | Acidic Nuclear Phosphoprotein 32 Family Member A |
| Gene Type | Protein coding |
| Chromosomal Location | 15q23 |
| NCBI Gene ID | 8125 ncbi.nlm.nih.gov/gene/8125 |
| Ensembl ID | ENSG00000140391 |
| UniProt ID | P39687 |
| OMIM ID | 600832 |
| HGNC ID | 558 |
| Aliases | PHAP1, I1PP2A, MAPM, C15orf1 |
Description
ANP32A encodes a member of the acidic nuclear phosphoprotein 32 family. This protein is involved in multiple cellular processes including regulation of gene expression, apoptosis, cell cycle control, and tumor suppression. It acts as a potent inhibitor of protein phosphatase 2A (PP2A) and also plays a role in the regulation of histone acetylation and chromatin remodeling. ANP32A has been implicated in various cancers and neurological conditions.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Altered expression and mutations may disrupt apoptosis and cell cycle regulation, contributing to tumorigenesis. | COSMIC, PubMed |
| Alzheimer's disease | ANP32A may modulate tau phosphorylation via PP2A inhibition, affecting neurodegeneration. | PubMed |
| Spinocerebellar ataxia | Potential involvement in polyglutamine toxicity pathways. | PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | High | High expression in neuronal tissues |
| Testis | Medium | Moderate expression |
| Lung | Low | Low expression |
| Liver | Low | Low expression |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | High | Cervical cancer cell line |
| A549 | Medium | Lung carcinoma cell line |
| MCF7 | Medium | Breast cancer cell line |
| HEK293 | High | Embryonic kidney cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.123A>G (p.I41M) | Missense | Rare | Potential functional impact on protein stability |
| c.456C>T (p.S152F) | Missense | Rare | May affect PP2A binding |
| c.789delC | Frameshift | Very rare | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and truncating mutations may lead to loss of tumor suppressor activity.
Gain of Function (GOF)
Some missense mutations may enhance oncogenic properties, though not well characterized.
Dominant Negative (DN)
Not clearly established; further research needed.
View complete mutation data：
Gene Ontology (GO)
| • protein phosphatase inhibitor activity | • histone binding |
| • chromatin binding | • protein binding |
| • nucleus | • cytoplasm |
| • regulation of apoptotic process | • negative regulation of cell cycle |
Pathways
• Apoptosis
• Cell cycle
• PP2A signaling
• Chromatin remodeling
Protein Summary
ANP32A is a 249-amino acid protein with an N-terminal leucine-rich repeat domain and a C-terminal acidic region. It is predominantly nuclear and functions as a tumor suppressor by inhibiting PP2A and regulating gene expression. It also interacts with histone acetyltransferases and deacetylases, influencing chromatin structure. Its expression is ubiquitous but highest in brain and testis. Mutations and altered expression are linked to cancer and neurodegenerative diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ANP32A Knockout HEK293 Cell Line | EDJ-KQ6175 | Human | 8125 | Details Get a Quote |
| ANP32A Knockout A-549 Cell Line | EDJ-KQ29996 | Human | 8125 | Details Get a Quote |
| ANP32A Knockout HCT 116 Cell Line | EDJ-KQ29997 | Human | 8125 | Details Get a Quote |
| ANP32A Knockout HeLa Cell Line | EDJ-KQ29998 | Human | 8125 | Details Get a Quote |
| ANP32A Knockout MDCK Cell Line | EDJ-KZ541 | Dog | 403534 | Details Get a Quote |
